1. |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
|
2. |
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med, 2016, 375(19): 1823-1833.
|
3. |
Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, 2019, 393(10183): 1819-1830.
|
4. |
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 2017, 389(10066): 255-265.
|
5. |
孙涛, 韩善清, 汪家旺. PET/CT 成像原理、优势及临床应用. 中国医学物理学杂志, 2010, 27(1): 1581-1582, 1587.
|
6. |
杨欣, 林冬梅. 2015 版 WHO 肺癌组织学分类变化及其临床意义. 中国肺癌杂志, 2016, 19(6): 332-336.
|
7. |
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012, 12(4): 252-264.
|
8. |
Soria JC, Marabelle A, Brahmer JR, et al. Immune checkpoint modulation for non-small cell lung cancer. Clin Cancer Res, 2015, 21(10): 2256-2262.
|
9. |
Wu YL, Lu S, Cheng Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase Ⅲ clinical trial. J Thorac Oncol, 2019, 14(5): 867-875.
|
10. |
Daskivich TJ, Belldegrun A. Words of wisdom. Re: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. Eur Urol, 2015, 67(4): 816-817.
|
11. |
Takada K, Toyokawa G, Tagawa T, et al. Association between PD-L1 expression and metabolic activity on 18F-FDG PET/CT in patients with small-sized lung cancer. Anticancer Res, 2017, 37(12): 7073-7082.
|
12. |
Takada K, Toyokawa G, Okamoto T, et al. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography. Cancer Med, 2017, 6(11): 2552-2561.
|
13. |
Kaira K, Shimizu K, Kitahara S, et al. 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma. Eur J Cancer, 2018, 101: 181-190.
|
14. |
林冬梅. 中国非小细胞肺癌 PD-L1 检测现状. 中华病理学杂志, 2017, 46(10): 665-668.
|
15. |
Scheel AH, Dietel M, Heukamp LC, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol, 2016, 29(10): 1165-1172.
|
16. |
赵宁, 任红亮, 潘娜, 等. 非小细胞肺癌组织 PD-L1 的表达及其与临床因素的关系. 中国肿瘤生物治疗杂志, 2017, 24(3): 284-289.
|
17. |
党亚萍, 刘刚, 王红, 等. PET/CT 对肺内结节诊断及治疗的临床价值. 中华肿瘤杂志, 2004, 26(11): 685-687.
|
18. |
Erasmus JJ, Rohren E, Swisher SG. Prognosis and reevaluation of lung cancer by positron emission tomography imaging. Proc Am Thorac Soc, 2009, 6(2): 171-179.
|
19. |
Yoshida T, Tanaka H, Kuroda H, et al. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs. Lung Cancer, 2016, 100: 14-19.
|
20. |
杜海磊, 车嘉铭, 朱良纲, 等. 病理 T1 期浸润性肺腺癌不同病理亚型的临床特征及其预后分析. 诊断学理论与实践, 2018, 17(1): 82-86.
|
21. |
Yoshida Y, Nitadori JI, Shinozaki-Ushiku A, et al. Micropapillary histological subtype in lung adenocarcinoma of 2 cm or less: impact on recurrence and clinical predictors. Gen Thorac Cardiovasc Surg, 2017, 65(5): 273-279.
|
22. |
Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol, 2009, 27(17): 2758-2765.
|
23. |
Park B, Lee G, Kim HK, et al. A retrospective comparative analysis of elderly and younger patients undergoing pulmonary resection for stage Ⅰ non-small cell lung cancer. World J Surg Oncol, 2016, 14(1): 13.
|
24. |
Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer, 2019, 135: 188-195.
|